578
Participants
Start Date
May 22, 2025
Primary Completion Date
June 29, 2025
Study Completion Date
June 29, 2025
BTOS-HA
Brimonidine tartrate ophthalmic solution 0.025% with sodium hyaluronate (BTOS-HA) administered as 1 topical ocular drop instilled into each eye (OU), 4 times daily (QID), approximately 4 hours apart
Lumify®
Brimonidine tartrate ophthalmic solution 0.025%, administered as 1 topical ocular drop instilled into each eye (OU), 4 times daily (QID), approximately 4 hours apart
Site 112, Cranberry Township
Site 108, Garner
Site 107, Shelby
Site 105, Smyrna
Site 101, Memphis
Site 106, Louisville
Site 111, Northbrook
Site 109, Pittsburg
Site 102, Glendale
Site 104, Newport Beach
Site 103, Andover
Bausch & Lomb Incorporated
INDUSTRY